Ainos, Inc. (AIMD)
NASDAQ: AIMD · IEX Real-Time Price · USD
2.05
0.00 (0.00%)
At close: Dec 29, 2023, 4:00 PM
1.97
-0.08 (-3.90%)
After-hours: Dec 29, 2023, 7:15 PM EST
Ainos Revenue
Ainos had revenue of $1.14M in the twelve months ending September 30, 2023, down -54.54% year-over-year. Revenue in the quarter ending September 30, 2023 was $24.49K, a -98.61% decrease year-over-year. In the year 2022, Ainos had annual revenue of $3.52M with 491.97% growth.
Revenue (ttm)
$1.14M
Revenue Growth
-54.54%
P/S Ratio
8.41
Revenue / Employee
$26,517
Employees
43
Market Cap
9.59M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 3.52M | 2.93M | 491.97% |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | 11.73K | -65.99K | -84.91% |
| Dec 31, 2018 | 77.72K | -173.20K | -69.03% |
| Dec 31, 2017 | 250.93K | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongchao | 17.23M |
| Precipio | 13.26M |
| Aravive | 7.00M |
| Aeterna Zentaris | 6.86M |
| Addex Therapeutics | 2.24M |
AIMD News
- 5 days ago - Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell - Accesswire
- 19 days ago - Ainos, Inc. Announces Stock Consolidation - Accesswire
- 4 weeks ago - Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical - Accesswire
- 5 weeks ago - Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA - Accesswire
- 7 weeks ago - Ainos Reports Third Quarter 2023 Financial Results - Accesswire
- 7 weeks ago - Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA - Accesswire
- 3 months ago - Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement - Accesswire
- 3 months ago - With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients - Newsfile Corp